Log in to save to my catalogue

Drug-regulated CD33-targeted CAR T cells control AML using clinically optimized rapamycin dosing

Drug-regulated CD33-targeted CAR T cells control AML using clinically optimized rapamycin dosing

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11060733

Drug-regulated CD33-targeted CAR T cells control AML using clinically optimized rapamycin dosing

Publication information

Publisher

United States: American Society for Clinical Investigation

More information

Scope and Contents

Contents

Chimeric antigen receptor (CAR) designs that incorporate pharmacologic control are desirable; however, designs suitable for clinical translation are needed. We designed a fully human, rapamycin-regulated drug product for targeting CD33+ tumors called dimerizaing agent-regulated immunoreceptor complex (DARIC33). T cell products demonstrated target-s...

Alternative Titles

Full title

Drug-regulated CD33-targeted CAR T cells control AML using clinically optimized rapamycin dosing

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11060733

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11060733

Other Identifiers

ISSN

1558-8238,0021-9738

E-ISSN

1558-8238

DOI

10.1172/JCI162593

How to access this item